Keymed Biosciences Announces the Latest Clinical Trial Results of CM336 Published in the New England Journal of Medicine - Thailand PR News - [Banking](https://thailandbusinessnews.net/category/banking/) - [Companies](https://thailandbusinessnews.net/category/companies/) - [Economy](https://thailandbusinessnews.net/category/economy/) - [Press Releases](https://thailandbusinessnews.net/category/press-release/) - [PR Newswire](https://thailandbusinessnews.net/pr-newswire-updates/) - [Tech](https://thailandbusinessnews.net/category/tech/) - [Tourism](https://thailandbusinessnews.net/category/tourism/) - [Press Release](https://thailandbusinessnews.net/category/press-release/) # Keymed Biosciences Announces the Latest Clinical Trial Results of CM336 Published in the New England Journal of Medicine ##### Up next ![SNEC 2025｜Hithium Defines a New Benchmark for Energy Storage Safety with the World's First All Open-Door Large-Scale Fire Test](https://i0.wp.com/thailandbusinessnews.net/wp-content/uploads/2025/06/Hithium_Booth.jpg?resize=200%2C110&ssl=1 "SNEC 2025｜Hithium Defines a New Benchmark for Energy Storage Safety with the World's First All Open-Door Large-Scale Fire Test") [](https://thailandbusinessnews.net/press-release/snec-2025%ef%bd%9chithium-defines-a-new-benchmark-for-energy-storage-safety-with-the-worlds-first-all-open-door-large-scale-fire-test/) ###### [SNEC 2025｜Hithium Defines a New Benchmark for Energy Storage Safety with the World's First All Open-Door Large-Scale Fire Test](https://thailandbusinessnews.net/press-release/snec-2025%ef%bd%9chithium-defines-a-new-benchmark-for-energy-storage-safety-with-the-worlds-first-all-open-door-large-scale-fire-test/) Published on 13 June 2025 ##### Author ##### [ CISION PRNewswire ](https://thailandbusinessnews.net/author/cision/) ##### Tags - [PRNewswire](https://thailandbusinessnews.net/tag/prnewswire/) CHENGDU, China, June 12, 2025 /PRNewswire/ — Keymed Biosciences Inc. (HKEX: 02162) today announced that Prof. Jun Shi’s research team from the Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences (Institute of Hematology, Chinese Academy of Medical Sciences) has recently published a research report titled "BCMA-Targeted T-Cell Engager for Autoimmune Hemolytic Anemia after CD19 CAR T-Cell Therapy" in the New England Journal of Medicine (NEJM), which has reported for the first time globally the research data on a BCMA x CD3 bispecific antibody treatment for patients with refractory autoimmune hemolytic anemia (AIHA). The study results showed that two patients experienced rapid disease improvement after the administration of CM336, achieving partial remission on days 13 and 19, respectively. Hemoglobin levels returned to normal on days 17 and 21, respectively, while reticulocyte counts, lactate dehydrogenase, and indirect bilirubin levels significantly decreased. Before receiving treatment with CM336, both patients had undergone multiple treatment regimens, including glucocorticoids, splenectomy, anti-CD20 antibodies, BTK inhibitors, and CD19 CAR-T cell therapies, but their disease eventually recurred or progressed to refractory status. The latest assessment results after 6 months post-starting CM336 showed that both patients remained in sustained remission without immunosuppressive therapies or transfusions. No cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), or infection events occurred during the entire treatment and follow-up period. The overall study showed that CM336 had demonstrated positive efficacy signals in treating patients with relapsed/refractory AIHA who had previously received multiple therapies, with rapid disease control and sustained remission lasting over half a year, while also exhibiting good safety profile, potentially making it an innovative treatment option for development in this disease. About CM336CM336 is a BCMA x CD3 bispecific antibody that can simultaneously target and identify and specifically bind both BCMA on the surface of target cells and the CD3 receptors on the surface of T cells to recruit immune T cells to the vicinity of the target cells, thereby inducing T-cell dependent cellular cytotoxicity (TDCC) to eliminate the target cells. As of the date of this announcement, the Phase II clinical study of CM336 for the treatment of primary light-chain amyloidosis has been approved by the Center for Drug Evaluation of the National Medical Products Administration and will commence clinical trials shortly. About Keymed BiosciencesKeymed Biosciences Inc. (HKEX: 02162) is a biotech company focused on the urgent unmet clinical needs, and committed to providing high-quality, affordable, innovative therapies for patients in China and overseas. Keymed was founded by medical and scientific experts who have strong experience in the transformation of scientific and technological achievements to commercialization at home and abroad. [Source link ](https://www.prnasia.com/story/archive/4709778_CN09778_0?rand=89749) ``` This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network ``` ##### You May Also Like [](https://thailandbusinessnews.net/press-release/inspire-media-communications-earns-14-no-1-rankings-in-agency-scope-china-2025-2026/) ![iNSPIRE Media & Communications Earns 14 No. 1 Rankings in Agency Scope China 2025/2026](https://i0.wp.com/mma.prnasia.com/media2/2959101/image1.jpg?resize=260%2C140&ssl=1 "iNSPIRE Media & Communications Earns 14 No. 1 Rankings in Agency Scope China 2025/2026") - [Press Release](https://thailandbusinessnews.net/category/press-release/) ## iNSPIRE Media & Communications Earns 14 No. 1 Rankings in Agency Scope China 2025/2026 Independent agency ranks No. 2 in client satisfaction among integrated marketing agencies… - [CISION PRNewswire](https://thailandbusinessnews.net/author/cision/ "View all posts by CISION PRNewswire") - April 21, 2026 [](https://thailandbusinessnews.net/press-release/datasea-achieves-breakthrough-in-acoustic-technology-accelerating-billion-dollar-commercialization-in-healthcare/) ## Datasea Achieves Breakthrough in Acoustic Technology, Accelerating Billion-Dollar Commercialization in Healthcare DTSS’ Acoustic innovation Addresses the Healthcare Application Market Projected to Exceed $100… - [CISION PRNewswire](https://thailandbusinessnews.net/author/cision/ "View all posts by CISION PRNewswire") - August 18, 2025 [](https://thailandbusinessnews.net/press-release/kucoin-showcases-kucard-at-tomorrowland-winter-reflecting-growing-interest-in-simpler-crypto-access/) ![KuCoin Showcases KuCard at Tomorrowland Winter, Reflecting Growing Interest in Simpler Crypto Access](https://i0.wp.com/mma.prnasia.com/media2/2785613/KuCoin_new_Logo.jpg?resize=260%2C140&ssl=1 "KuCoin Showcases KuCard at Tomorrowland Winter, Reflecting Growing Interest in Simpler Crypto Access") - [Press Release](https://thailandbusinessnews.net/category/press-release/) ## KuCoin Showcases KuCard at Tomorrowland Winter, Reflecting Growing Interest in Simpler Crypto Access The activation highlights KuCoin’s broader vision of connecting digital finance, culture, and everyday… - [CISION PRNewswire](https://thailandbusinessnews.net/author/cision/ "View all posts by CISION PRNewswire") - March 25, 2026 ##### Most Read - [![CMC REIT Steadily Advances Strategic Transformation in 2026 Interim Results](https://secure.gravatar.com/avatar/96e712b5408b51145de772098c3ff3417ce8a11555b7c388d84204c5769f5631?s=40&d=blank&r=g)](https://thailandbusinessnews.net/press-release/cmc-reit-steadily-advances-strategic-transformation-in-2026-interim-results/ "CMC REIT Steadily Advances Strategic Transformation in 2026 Interim Results") [CMC REIT Steadily Advances Strategic Transformation in 2026 Interim Results](https://thailandbusinessnews.net/press-release/cmc-reit-steadily-advances-strategic-transformation-in-2026-interim-results/ "CMC REIT Steadily Advances Strategic Transformation in 2026 Interim Results") - [![UOB Poll Finds SMEs Keen on AI but Struggle to Move Beyond Pilot Stage](https://secure.gravatar.com/avatar/96e712b5408b51145de772098c3ff3417ce8a11555b7c388d84204c5769f5631?s=40&d=blank&r=g)](https://thailandbusinessnews.net/press-release/uob-poll-finds-smes-keen-on-ai-but-struggle-to-move-beyond-pilot-stage/ "UOB Poll Finds SMEs Keen on AI but Struggle to Move Beyond Pilot Stage") [UOB Poll Finds SMEs Keen on AI but Struggle to Move Beyond Pilot Stage](https://thailandbusinessnews.net/press-release/uob-poll-finds-smes-keen-on-ai-but-struggle-to-move-beyond-pilot-stage/ "UOB Poll Finds SMEs Keen on AI but Struggle to Move Beyond Pilot Stage") - [![Joget Introduces Agent Lab, a Program Helping Businesses Build AI Agents Without Code](https://secure.gravatar.com/avatar/96e712b5408b51145de772098c3ff3417ce8a11555b7c388d84204c5769f5631?s=40&d=blank&r=g)](https://thailandbusinessnews.net/press-release/joget-introduces-agent-lab-a-program-helping-businesses-build-ai-agents-without-code/ "Joget Introduces Agent Lab, a Program Helping Businesses Build AI Agents Without Code") [Joget Introduces Agent Lab, a Program Helping Businesses Build AI Agents Without Code](https://thailandbusinessnews.net/press-release/joget-introduces-agent-lab-a-program-helping-businesses-build-ai-agents-without-code/ "Joget Introduces Agent Lab, a Program Helping Businesses Build AI Agents Without Code") - [![Russell Reynolds Associates Announces Nick Fletcher as Australia Country Leader](https://secure.gravatar.com/avatar/96e712b5408b51145de772098c3ff3417ce8a11555b7c388d84204c5769f5631?s=40&d=blank&r=g)](https://thailandbusinessnews.net/press-release/russell-reynolds-associates-announces-nick-fletcher-as-australia-country-leader/ "Russell Reynolds Associates Announces Nick Fletcher as Australia Country Leader") [Russell Reynolds Associates Announces Nick Fletcher as Australia Country Leader](https://thailandbusinessnews.net/press-release/russell-reynolds-associates-announces-nick-fletcher-as-australia-country-leader/ "Russell Reynolds Associates Announces Nick Fletcher as Australia Country Leader") - [![Hyundai Motor Company Charts Profit-Driven Growth Roadmap at 2026 CEO Investor Day](https://secure.gravatar.com/avatar/96e712b5408b51145de772098c3ff3417ce8a11555b7c388d84204c5769f5631?s=40&d=blank&r=g)](https://thailandbusinessnews.net/press-release/hyundai-motor-company-charts-profit-driven-growth-roadmap-at-2026-ceo-investor-day/ "Hyundai Motor Company Charts Profit-Driven Growth Roadmap at 2026 CEO Investor Day") [Hyundai Motor Company Charts Profit-Driven Growth Roadmap at 2026 CEO Investor Day](https://thailandbusinessnews.net/press-release/hyundai-motor-company-charts-profit-driven-growth-roadmap-at-2026-ceo-investor-day/ "Hyundai Motor Company Charts Profit-Driven Growth Roadmap at 2026 CEO Investor Day") - [![Voltage Energy Will Seek New Trial and Review of Verdict in Shoals Patent Dispute](https://secure.gravatar.com/avatar/96e712b5408b51145de772098c3ff3417ce8a11555b7c388d84204c5769f5631?s=40&d=blank&r=g)](https://thailandbusinessnews.net/press-release/voltage-energy-will-seek-new-trial-and-review-of-verdict-in-shoals-patent-dispute/ "Voltage Energy Will Seek New Trial and Review of Verdict in Shoals Patent Dispute") [Voltage Energy Will Seek New Trial and Review of Verdict in Shoals Patent Dispute](https://thailandbusinessnews.net/press-release/voltage-energy-will-seek-new-trial-and-review-of-verdict-in-shoals-patent-dispute/ "Voltage Energy Will Seek New Trial and Review of Verdict in Shoals Patent Dispute") ##### Subscribe via Email Enter your email address to subscribe and receive notifications of new posts by email. Email Address Subscribe [](https://thailandbusinessnews.net/press-release/kazia-therapeutics-limited-announces-proposed-public-offering/) ## Kazia Therapeutics Limited Announces Proposed Public Offering SYDNEY, Aug. 28, 2026 /PRNewswire/ — Kazia Therapeutics Limited (NASDAQ:… [](https://thailandbusinessnews.net/press-release/kazia-therapeutics-reports-100-clinical-benefit-rate-in-initial-six-patients-treated-for-advanced-triple-negative-breast-cancer/) ## Kazia Therapeutics Reports 100% Clinical Benefit Rate in Initial Six Patients Treated for Advanced Triple-Negative Breast Cancer Durable Complete Metabolic Response Ongoing Since November 2025 All Evaluable Patients… [](https://thailandbusinessnews.net/press-release/global-genomics-and-multi-omics-leader-novogene-to-establish-its-first-australian-laboratory-at-cabrini-health-accelerating-access-to-precision-cancer-care/) ![Global genomics and multi-omics leader Novogene to establish its first Australian laboratory at Cabrini Health, accelerating access to precision cancer care](https://i0.wp.com/mmx.prnasia.com/media/MS1976829/20260827035513EDT_image_1.jpg?resize=260%2C140&ssl=1 "Global genomics and multi-omics leader Novogene to establish its first Australian laboratory at Cabrini Health, accelerating access to precision cancer care") ## Global genomics and multi-omics leader Novogene to establish its first Australian laboratory at Cabrini Health, accelerating access to precision cancer care MELBOURNE, Australia, Aug. 28, 2026 /PRNewswire/ — Global multi-omics leader… [](https://thailandbusinessnews.net/press-release/tutti-vm-launches-in-early-access-the-google-docs-moment-for-cross-agent-collaboration/) ![Tutti • VM Launches in Early Access: The Google Docs Moment for Cross-Agent Collaboration](https://i0.wp.com/mmx.prnasia.com/media/MS1973504/20260821015411EDT_image_3.jpg?resize=260%2C140&ssl=1 "Tutti • VM Launches in Early Access: The Google Docs Moment for Cross-Agent Collaboration") ## Tutti • VM Launches in Early Access: The Google Docs Moment for Cross-Agent Collaboration Local agents stay local and identity never leaves the machine, while multi-layer…